• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Zier Dawn M. was granted 2,094 shares, increasing direct ownership by 15% to 16,533 units (SEC Form 4)

    8/6/25 4:04:46 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    ZIER DAWN M.

    (Last) (First) (Middle)
    660 WHITE PLAINS ROAD

    (Street)
    TARRYTOWN NY 10591

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Prestige Consumer Healthcare Inc. [ PBH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    08/05/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, par value $0.01 per share 08/05/2025 A 2,094(1) A $0 16,533 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The Reporting Person received 2,094 restricted stock units equal to $155,000 divided by the closing stock price of $74.04 on August 5, 2025, in connection with the Issuer's director compensation program. The restricted stock units vest on the first anniversary of grant and will be settled by delivery to the Reporting Person of one share of common stock of the issuer for each vested restricted stock unit promptly following the earliest of (1) the Reporting Person's death, (ii) the Reporting Person's separation or (iii) change in control.
    /s/ Dawn M. Zier by Christine Sacco Attorney-in-Fact pursuant to Power of Attorney dated May 4, 2020 on file with the Commission 08/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PBH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PBH

    DatePrice TargetRatingAnalyst
    9/24/2025$80.00Neutral → Buy
    Sidoti
    12/9/2024$90.00Buy → Neutral
    Sidoti
    6/21/2024$65.00 → $93.00Neutral → Buy
    DA Davidson
    11/17/2022$71.00Buy
    Canaccord Genuity
    5/10/2022$65.00 → $70.00Hold → Buy
    Jefferies
    5/9/2022$63.00Perform → Outperform
    Oppenheimer
    3/11/2022$156.00 → $142.00Outperform
    BMO Capital
    11/15/2021$61.00 → $63.00Neutral
    DA Davidson
    More analyst ratings

    $PBH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Prestige Consumer Healthcare Inc.

    SCHEDULE 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    8/13/25 4:14:05 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Prestige Consumer Healthcare Inc.

    10-Q - Prestige Consumer Healthcare Inc. (0001295947) (Filer)

    8/7/25 6:15:06 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Prestige Consumer Healthcare Inc. (0001295947) (Filer)

    8/7/25 6:07:11 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Prestige Consumer Healthcare to Release Fiscal 2026 Second Quarter Earnings Results

    TARRYTOWN, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 second quarter and first half earnings release on Thursday, November 6, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to joi

    10/6/25 5:00:00 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare to Present at the Barclays Global Consumer Staples Conference

    TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced it will present at the Barclays Global Consumer Staples Conference on Thursday, September 4, 2025 at 12:45 p.m. ET. All interested parties may access a live webcast of this event at www.prestigeconsumerhealthcare.com under the "Investors" section and the "Events and Presentations" tab, or by using the following link: https://ir.prestigebrands.com/events-presentations/events For those unable to participate during the live webcast, a replay option will be available on the Company's website following the event. About Prestige Consumer Healthcare Inc. Prestige Consumer H

    9/4/25 7:00:03 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare Inc. Reports Fiscal 2026 First Quarter Results

    Revenue of $249.5 million in Q1; decline driven by limited eye care supplyDiluted EPS of $0.95 in Q1, up approximately 6% versus prior year Adjusted Diluted EPS of $0.90Announces agreement to acquire current eye care supplier Pillar5 PharmaRevising fiscal 2026 revenue outlook to $1,100 to $1,115 million and Diluted EPS outlook to $4.50 to $4.58 TARRYTOWN, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter fiscal 2026 ended June 30, 2025. "We experienced momentum in multiple areas of our business in the first quarter, including strong international segment growth, year-over-year improvement in gross m

    8/7/25 6:00:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Prestige Consumer upgraded by Sidoti with a new price target

    Sidoti upgraded Prestige Consumer from Neutral to Buy and set a new price target of $80.00

    9/24/25 7:53:30 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer downgraded by Sidoti with a new price target

    Sidoti downgraded Prestige Consumer from Buy to Neutral and set a new price target of $90.00

    12/9/24 9:05:37 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer upgraded by DA Davidson with a new price target

    DA Davidson upgraded Prestige Consumer from Neutral to Buy and set a new price target of $93.00 from $65.00 previously

    6/21/24 7:05:28 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kelly John F. was granted 2,094 shares, increasing direct ownership by 76% to 4,851 units (SEC Form 4)

    4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

    8/6/25 4:05:36 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Zier Dawn M. was granted 2,094 shares, increasing direct ownership by 15% to 16,533 units (SEC Form 4)

    4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

    8/6/25 4:04:46 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hopkins Sheila was granted 2,094 shares, increasing direct ownership by 7% to 30,123 units (SEC Form 4)

    4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

    8/6/25 4:03:43 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Leadership Updates

    Live Leadership Updates

    View All

    Better For You Wellness Announces Results from Its February 5, 2022, Board of Directors Meeting

    Better For You Wellness Establishes Strategic Advisory Committee with Industry Leaders and MoreColumbus, Ohio--(Newsfile Corp. - February 10, 2022) - Better For You Wellness, Inc. (OTCQB:BFYW) ("Better For You Wellness" or the "Company"), an Ohio-based company focused on the rapidly-growing $1.5T wellness industry, is pleased to announce the results of the Meeting of the Board of Directors that took place on February 5, 2022, via video conference (the "Board Meeting"). The seven members of the Company's Board of Directors (the "Board") include Ian James, Stephen Letourneau, Montel Williams, Christina Jefferson, Joseph Watson, David Deming, and Dr. Nicola Finley, MD.Establishment of Strategic

    2/10/22 3:58:00 PM ET
    $LEAF
    $PBH
    $SPTN
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Financials

    Live finance-specific insights

    View All

    Prestige Consumer Healthcare to Release Fiscal 2026 Second Quarter Earnings Results

    TARRYTOWN, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 second quarter and first half earnings release on Thursday, November 6, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to joi

    10/6/25 5:00:00 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare Inc. Reports Fiscal 2026 First Quarter Results

    Revenue of $249.5 million in Q1; decline driven by limited eye care supplyDiluted EPS of $0.95 in Q1, up approximately 6% versus prior year Adjusted Diluted EPS of $0.90Announces agreement to acquire current eye care supplier Pillar5 PharmaRevising fiscal 2026 revenue outlook to $1,100 to $1,115 million and Diluted EPS outlook to $4.50 to $4.58 TARRYTOWN, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter fiscal 2026 ended June 30, 2025. "We experienced momentum in multiple areas of our business in the first quarter, including strong international segment growth, year-over-year improvement in gross m

    8/7/25 6:00:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare to Release Fiscal 2026 First Quarter Earnings Results

    TARRYTOWN, N.Y., July 15, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 first quarter earnings release on Thursday, August 7, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes

    7/15/25 8:00:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Prestige Consumer Healthcare Inc.

    SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    2/14/24 10:11:25 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Prestige Consumer Healthcare Inc.

    SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    2/14/24 7:09:49 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Prestige Consumer Healthcare Inc. (Amendment)

    SC 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    2/13/24 5:12:15 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care